The world's first new antidiabetic drug Huatangning ® was approved, and Bayer established a diabetes whole course management model

Beijing, October 9, 2022 – Bayer announces that the National Medicines Administration has approved Huatangin (Doglidine Tablets), the world's first innovative drug for diabetes, for use alone or, in combination with metformin ^® hydrochloride when blood sugar control is poor, in combination with diet and exercise to improve blood sugar control

The approved Huadoning ^® is the world's first oral hypoglycemic drug with a new mechanism, which will provide innovative treatment options

In the normal physiological state, the fluctuation of the body's blood glucose level is maintained in the narrow range of 3.

Huadoning's ^® approval is based on two key milestones in the Phase III new drug launch registration clinical trial – the SEED study and the DAWN study

Huadonin ^® also demonstrated significant efficacy and safety advantages

Dr.

About Hua Doning ®

Huatangin (Dopaglidine Tablets) is a world-first, new-mechanism glucokinase activator for use alone or, in combination with metformin hydrochloride in combination with diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus when the glycemic control

About Hua Ling Hua Ling

About the cooperation between Hua Ling and Bayer

In August 2020, Bayer, a multinational pharmaceutical company, and Hua Ling Pharmaceutical, an innovative drug research and development company in China, announced the establishment of a strategic cooperation in

About Bayer

As a global company, Bayer has core competencies